Nascent Biotech (Nascent Biotech) FCF Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Nascent Biotech FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Nascent Biotech's Free Cash Flow for the three months ended in Dec. 2023 was $-0.33 Mil. Nascent Biotech's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Therefore, Nascent Biotech's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

As of today, Nascent Biotech's current FCF Yield % is -7.38%.

The historical rank and industry rank for Nascent Biotech's FCF Margin % or its related term are showing as below:

During the past 7 years, the highest FCF Margin % of Nascent Biotech was 41.30%. The lowest was -131.60%. And the median was -25.63%.

NBIO's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -143.92
* Ranked among companies with meaningful FCF Margin % only.

Nascent Biotech FCF Margin % Historical Data

The historical data trend for Nascent Biotech's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nascent Biotech FCF Margin % Chart

Nascent Biotech Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

FCF Margin %

Get a 7-Day Free Trial

-131.60

41.30

Nascent Biotech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Nascent Biotech's FCF Margin %

For the Biotechnology subindustry, Nascent Biotech's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nascent Biotech's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nascent Biotech's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Nascent Biotech's FCF Margin % falls into.

Nascent Biotech FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Nascent Biotech's FCF Margin for the fiscal year that ended in Mar. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Mar. 2023 )	/	Revenue (A: Mar. 2023 )
	=	-1.787	/	0
	=	%

Nascent Biotech's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-0.33	/	0
	=	%

Nascent Biotech FCF Margin % Related Terms

Thank you for viewing the detailed overview of Nascent Biotech's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Nascent Biotech (Nascent Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nascent Biotech Inc (OTCPK:NBIO) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

631 US Hwy 1, Suite 407, N Palm Beach, FL, USA, 33408

Website

https://www.nascentbiotech.com

Nascent Biotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is focused on the development and delivery of human antibodies and cytokine responses to the treatment of cancer. The company's products include Pritumumab, CLNH5, and MultiPharm. The company is actively engaged in the development of Pritumumab which would be used for the treatment of brain cancer and pancreatic cancer. The company is also exploring the use of Pritumumab against other viruses.

Executives

Lowell Thomas Holden	director, officer: CFO	631 US HWY 1, SUITE 407, NORTH PALM BEACH FL 33408
Sean Carrick	director, officer: President	631 US HWY 1, SUITE 407, NORTH PALM BEACH FL 33408
Brandon Price	director, officer: Senior VP Business Development	6330 NANCY RIDGE DR., SUITE 105, SAN DIEGO CA 92121
Douglas John Karas	director	631 US HWY 1, SUITE 407, NORTH PALM BEACH FL 33408
Mark Glassy	director, officer: CEO	6330 NANCY RIDGE DR., SUITE 105, SAN DIEGO CA 92121